These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37851053)

  • 1. Impact of sequencing of androgen receptor-signaling inhibition and radiotherapy in prostate cancer: importance of homologous recombination disruption.
    Allen SG; Zhang C; Malone S; Roy S; Dess RT; Jackson WC; Mehra R; Speers C; Chinnaiyan AM; Sun Y; Spratt DE
    World J Urol; 2023 Dec; 41(12):3877-3887. PubMed ID: 37851053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Zhu Y; Dalrymple SL; Coleman I; Zheng SL; Xu J; Hooper JE; Antonarakis ES; De Marzo AM; Meeker AK; Nelson PS; Isaacs WB; Denmeade SR; Luo J; Brennen WN; Isaacs JT
    Oncogene; 2020 Nov; 39(45):6935-6949. PubMed ID: 32989253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor signaling regulates DNA repair in prostate cancers.
    Polkinghorn WR; Parker JS; Lee MX; Kass EM; Spratt DE; Iaquinta PJ; Arora VK; Yen WF; Cai L; Zheng D; Carver BS; Chen Y; Watson PA; Shah NP; Fujisawa S; Goglia AG; Gopalan A; Hieronymus H; Wongvipat J; Scardino PT; Zelefsky MJ; Jasin M; Chaudhuri J; Powell SN; Sawyers CL
    Cancer Discov; 2013 Nov; 3(11):1245-53. PubMed ID: 24027196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.
    Hinneh JA; Gillis JL; Mah CY; Irani S; Shrestha RK; Ryan NK; Atsushi E; Nassar ZD; Lynn DJ; Selth LA; Kato M; Centenera MM; Butler LM
    Br J Cancer; 2023 Oct; 129(8):1350-1361. PubMed ID: 37673961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1.
    Melnyk JE; Steri V; Nguyen HG; Hwang YC; Gordan JD; Hann B; Feng FY; Shokat KM
    Oncogene; 2022 Mar; 41(11):1536-1549. PubMed ID: 35087237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
    Scher HI; Graf RP; Schreiber NA; McLaughlin B; Lu D; Louw J; Danila DC; Dugan L; Johnson A; Heller G; Fleisher M; Dittamore R
    Eur Urol; 2017 Jun; 71(6):874-882. PubMed ID: 27979426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
    Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
    Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
    Sperger JM; Emamekhoo H; McKay RR; Stahlfeld CN; Singh A; Chen XE; Kwak L; Gilsdorf CS; Wolfe SK; Wei XX; Silver R; Zhang Z; Morris MJ; Bubley G; Feng FY; Scher HI; Rathkopf D; Dehm SM; Choueiri TK; Halabi S; Armstrong AJ; Wyatt AW; Taplin ME; Zhao SG; Lang JM
    J Clin Oncol; 2021 Sep; 39(26):2926-2937. PubMed ID: 34197212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Androgen Receptor Does Not Directly Regulate the Transcription of DNA Damage Response Genes.
    Hasterok S; Scott TG; Roller DG; Spencer A; Dutta AB; Sathyan KM; Frigo DE; Guertin MJ; Gioeli D
    Mol Cancer Res; 2023 Dec; 21(12):1329-1341. PubMed ID: 37698543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.
    Ciccarese C; Iacovelli R; Sternberg CN; Gillessen S; Tortora G; Fizazi K
    Eur J Cancer; 2022 Sep; 173():276-284. PubMed ID: 35964470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer.
    Graf RP; Hullings M; Barnett ES; Carbone E; Dittamore R; Scher HI
    Eur Urol; 2020 Feb; 77(2):170-177. PubMed ID: 31648903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
    Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
    Jan YJ; Yoon J; Chen JF; Teng PC; Yao N; Cheng S; Lozano A; Chu GCY; Chung H; Lu YT; Chen PJ; Wang JJ; Lee YT; Kim M; Zhu Y; Knudsen BS; Feng FY; Garraway IP; Gao AC; Chung LWK; Freeman MR; You S; Tseng HR; Posadas EM
    Theranostics; 2019; 9(10):2812-2826. PubMed ID: 31244925
    [No Abstract]   [Full Text] [Related]  

  • 16. Androgen receptor splicing variant 7 (ARv7) promotes DNA damage response in prostate cancer cells.
    Luo H; Liu Y; Li Y; Zhang C; Yu B; Shao C
    FASEB J; 2022 Sep; 36(9):e22495. PubMed ID: 35947121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
    Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S
    Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
    Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C
    EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
    Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.